Status:
COMPLETED
Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation
Lead Sponsor:
Klinikum Ludwigshafen
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Previous clinical investigations have demonstrated the utility of β-adrenergic blockade in reducing perioperative ischaemic events, ultimately translating into a decrease in cardiac morbidity and mort...
Detailed Description
Cardiac complications, such as, myocardial infarction, heart failure, and life-threatening dysrhythmias, are the leading cause of perioperative death among patients undergoing major vascular surgery. ...
Eligibility Criteria
Inclusion
- scheduled for major vascular surgery
- can sign informed consent before surgery
- documented CAD or risk factors for CAD
Exclusion
- Preoperative treatment with beta-adrenergic agonists or glucocorticoids,
- electrocardiographic (ECG) abnormalities like nonsinus rhythm, second- or third degree heart block, or left bundle branch block,
- cardiac pacemaker dependency,
- symptomatic mitral or aortic valvular disease,
- a history of asthma, bronchospasm, or severe chronic obstructive pulmonary disease necessitating bronchodilator therapy,
- severe liver dysfunction
- known allergies against the study drugs
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00348101
Start Date
June 1 2006
End Date
May 1 2007
Last Update
May 30 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Intensive Care Medicine Klinikum Ludwigshafen
Ludwigshafen, Germany, 67063